Navidea Biopharmaceuticals has taken out a licensing agreement with Alseres Pharmaceuticals, Inc. The licensing agreement is for [123I]-E-IACFT Injection (CFT), an Iodine-123 radiolabeled imaging agent being developed as an aid in the diagnosis of Parkinson's disease and other movement disorders, with a potential use as a diagnostic aid in dementia. The agreement grants Navidea an exclusive, worldwide sub-license to research, develop and commercialise CFT, for which Alseres will earn a one-time sub-license execution payment equal to $175,000 and 300,000 shares of NAVB common stock.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 USD | -50.00% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 30 | |
-21.18% | 1.48B | |
-17.49% | 57.39M |
- Stock Market
- Equities
- ALSE Stock
- News Alseres Pharmaceuticals, Inc.
- Alseres Pharmaceuticals, Inc. Taken Out Licensing Agreement with Alseres Pharmaceuticals, Inc